Semaglutide is a GLP-1 receptor agonist
AS-IV has been shown to exert a range of pharmacological effects, including antioxidant, anti-inflammatory, and cardioprotective actions, which can mitigate the damage caused by these risk factors
In contrast to our previous observations in lean mice, ob/ob mice dosed with 0.1 g kg 1 of P5 or Ex4 showed a similar correction of glucose clearance in response to a glucose challenge (Supplementary Fig
More research and strong clinical trials on ketamine can help expand insurance coverage
The American Association of Clinical Endocrinologists/American College of Endocrinology consensus statement also recommends either a GLP-1RA or SGLT2i as a preferred treatment option (either as first-line or, more typically, second-line treatment after metformin) over alternative options such as a dipeptidyl peptidase-4 inhibitor, a thiazolidinedione (TZD), or a sulfonylurea (SU), for patients with T2D and ASCVD, stage 3 CKD, or heart failure with reduced ejection fraction [2]